Drug Trial Radar · NCT02866032
Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
Last checked: Nov 20, 2026Latest source record: Oct 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
452
Actual
Start
Sep 2016
Primary completion
Jun 10, 2020
Study completion Jun 10, 2020
Sponsor
- Lead sponsor
- Moberg Pharma ABIndustry
- Sponsor type
- Industry
- First posted
- Aug 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Who can join
- All sexes, from 18 years, up to 75 years
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of topical MOB015B in patients with mild to moderate distal subungual onychomycosis (DSO). The secondary objective is to evaluate the safety of topical MOB015B in patients with mild to moderate DSO.
Conditions
- Distal Subungual Onychomycosis
Interventions
MOB015BDrug
Ciclopirox 80 mg/gDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete cure of the target nail defined as negative fungal culture of dermatophytes, negative direct KOH microscopy and 0% clinical disease involvement at Week 52Time frame: Week 52
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
Multiple Locations, Germany
Site not named
Multiple Locations, Poland
Site not named
Multiple Locations, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.